Kelun Pharmaceutical announced on October 8 that as of September 30, 2026, the company had repurchased 350,000 shares, accounting for 0.02% of total share capital, with a repurchase amount of 10.37 million yuan and a repurchase price range of 29.55 yuan to 29.702 yuan per share. In the first half of 2026, Kelun Pharmaceutical achieved revenue of 8.839 billion yuan and net profit attributable to the parent company of 1.128 billion yuan.
Sichuan Kelun Pharmaceutical Co LtdKelun Pharmaceutical repurchased 350,000 shares for 10.37 million yuan, a buyback that is a financial/valuation event.
